Expression of selected regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer and their clinical significance

European Archives of Oto-Rhino-Laryngology

Volumn 270, Issue 10, 2013, Pages 2683-2693

  Klatka, Janusz ^a   Grywalska, Ewelina ^a   Klatka, Maria ^a   Wasiak, Magdalena ^a   Andrzejczak, Adrian ^a   Rolinski, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

B7H1; B7H4; CD200; CD200R; Cell lysates; Laryngeal cancer; Monocyte derived dendritic cells

Indexed keywords

CD200 ANTIGEN; CD83 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER PATIENT; CELL LYSATE; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; LARYNX CANCER; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD274; ANTIGENS, SURFACE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; LARYNGEAL NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOCYTES; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84883487037     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-013-2510-4     Document Type: Article

References (31)

1. Yu Q, Zhang X, Ji C, Yang H, Gao M, Hong S, Hu G (2012) Survival analysis of laryngeal carcinoma without laryngectomy, radiotherapy, or chemotherapy. Eur Arch Otorhinolaryngol 269:2103-2109
2. Chen YF, Luo RZ, Li Y, Cui BK, Song M, Yang AK, Chen WK (2013) High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 270:1009-1017
3. Seiferlein E, Haderlein T, Schuster M, Gräßel E, Bohr C (2012) Correlation between coping strategies and subjective assessment of the voice-related quality of life of patients after resection of T1 and T2 laryngeal tumours. Eur Arch Otorhinolaryngol 269:2091-2096
4. Sakakura K, Chikamatsu K, Takahashi K, Whiteside T, Furuya N (2006) Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 55:151-159
5. Pletinckx K, Döhler A, Pavlovic V, Lutz MB (2011) Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T-cells. Front Immunol 2:39. doi: 10.3389/fimmu.2011. 00039
6. Ichikawa M, Chen L (2005) Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Front Biosci 10:2856-2860
7. Zheng X, Li XD, Wu CP, Lu BF, Jiang JT (2012) Expression of costimulatory molecule B7-H4 in human malignant tumors. Onkologie 3511:700-705
8. Barclay AN, Clark MJ, McCaughan GW (1986) Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp 51:149-157
9. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103:1041-1046
10. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN (2001) The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102:173-179
11. Wong KK, Khatri I, Shaha S, Spaner DE, Gorczynski RM (2010) The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 88:361-372
12. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM (2010) The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res 70:2962-2972
13. Hadden JW (1997) The immunopharmacology of head and neck cancer: an update. Int J Immunopharmacol 11(12):629-644
14. Richtsmeier WJ (1997) Immunology of head and neck cancer. Bull Am Coll Surg 82:32-53
15. Hoek RM, Ruuls SR, Murphy CA (2000) Down: regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768-1771
16. Wright GJ, Puklavec MJ, Willis AC (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13:233-242
17. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA (2004) CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 172:7744-7749
18. Njau MN, Jacob J (2013) The CD28/B7 pathway: a novel regulator of plasma cell function. Adv Exp Med Biol 785:67-75
19. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K (2005) Blockade of B7-H1 on macrophages suppresses CD4+ T-cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 175:1586-1592
20. Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J (2010) B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. J Immunol 184:5466-5474
21. Kim HK, Guan H, Zu G, Li H, Wu L, Feng X et al (2006) High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. J Leukoc Biol 79:686-695
22. Qian Y, Shen L, Xu C, Wu Z, Brockmeyer NH, Altmeyer P, Wu N, Yao HP (2011) Development of a novel monoclonal antibody to B7-H4: characterization and biological activity. Eur J Med Res 16:295-302
23. Fields RC, Shimizu K, Mulé JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482-9487
24. Asavaroengchai W, Kotera Y, Mulé JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99:931-936
25. Gorczynski L, Chen Z, Hu J, Kai G, Ramakrishna V, Gorczynski RM (1999) Evidence that an OX-2 positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. J Immunol 162:774-781
26. Borriello F, Lederer J, Scott S, Sharpe AH (1997) MRC OX-2 defines a novel T cell costimulatory pathway. J Immunol 158:45-49
27. Hoek RM, Ruuls SR, Murphy CA (2000) Down: regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290:1768-1771
28. Rosenblum MD, Olasz E, Woodliff JE (2004) CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood 103:2691-2698
29. Seeds RE, Mukhopadhyay S, Jones IM, Gordon S, Miller JL (2011) The role of myeloid receptors on murine plasmacytoid dendritic cells in induction of type I interferon. Int Immunopharmacol 11:794-801
30. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS (2008) Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 180:699-705
31. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178:5595-5605